

Amendments to the Claims:

Claim 1 (Currently Amended): An isolated glycoprotein comprising ~~at least one~~ section of the human amino acid primary structure of CD55 and a tumor-specific glycostructure, wherein said glycoprotein has an apparent molecular weight of about 82 kD and is a glycoprotein present on a stomach carcinoma cell adenocarcinoma cell line 23132 (DSMZ Accession No. DSM ACC 201) or 3051 (DSMZ Accession No. DSM ACC 270), but not on a normal cell.

Claims 2-3 (Canceled).

Claim 4 (Previously Presented): A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by size-exclusion chromatography.

Claims 5-41 (Canceled).

Claim 42 (Previously Presented): A process for obtaining a glycoprotein according to claim 1, comprising producing a membrane preparation from cells of the human adenocarcinoma cell line 23132, and obtaining the glycoprotein therefrom by anion-exchange chromatography.

Claim 43 (Currently Amended): ~~An~~ The isolated glycoprotein of claim 1 ~~comprising at least one section of the human amino acid primary structure of CD55 and a tumor-specific glycostructure~~, wherein said glycoprotein, if present on a cell and bound by an antibody that is specific for said glycostructure, results in apoptosis of said cell.

Claim 44 (Canceled).